JPWO2023204278A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2023204278A5
JPWO2023204278A5 JP2024516313A JP2024516313A JPWO2023204278A5 JP WO2023204278 A5 JPWO2023204278 A5 JP WO2023204278A5 JP 2024516313 A JP2024516313 A JP 2024516313A JP 2024516313 A JP2024516313 A JP 2024516313A JP WO2023204278 A5 JPWO2023204278 A5 JP WO2023204278A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
atom
group
disease
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024516313A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023204278A1 (https=
Publication date
Priority claimed from PCT/JP2022/037909 external-priority patent/WO2023203791A1/ja
Application filed filed Critical
Priority claimed from PCT/JP2023/015821 external-priority patent/WO2023204278A1/ja
Publication of JPWO2023204278A1 publication Critical patent/JPWO2023204278A1/ja
Publication of JPWO2023204278A5 publication Critical patent/JPWO2023204278A5/ja
Pending legal-status Critical Current

Links

JP2024516313A 2022-04-21 2023-04-20 Pending JPWO2023204278A1 (https=)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2022070348 2022-04-21
JP2022112701 2022-07-13
PCT/JP2022/037909 WO2023203791A1 (ja) 2022-04-21 2022-10-11 医薬組成物、吸着方法、治療方法および予防方法
JP2022163375 2022-10-11
PCT/JP2023/015821 WO2023204278A1 (ja) 2022-04-21 2023-04-20 医薬組成物、吸着方法、治療方法および予防方法

Publications (2)

Publication Number Publication Date
JPWO2023204278A1 JPWO2023204278A1 (https=) 2023-10-26
JPWO2023204278A5 true JPWO2023204278A5 (https=) 2024-12-25

Family

ID=88419979

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024516314A Pending JPWO2023204279A1 (https=) 2022-04-21 2023-04-20
JP2024516313A Pending JPWO2023204278A1 (https=) 2022-04-21 2023-04-20

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2024516314A Pending JPWO2023204279A1 (https=) 2022-04-21 2023-04-20

Country Status (5)

Country Link
US (2) US20250032694A1 (https=)
EP (1) EP4491187A4 (https=)
JP (2) JPWO2023204279A1 (https=)
CN (2) CN119031922A (https=)
WO (2) WO2023204279A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120305284A (zh) * 2024-01-12 2025-07-15 株式会社村田制作所 药物组合物、肠道菌群的改善方法、治疗方法和预防方法
WO2025225525A1 (ja) * 2024-04-26 2025-10-30 株式会社村田製作所 導電性粒子、フィルム、ペースト、コンポジット材料、および導電性粒子の製造方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11278862B2 (en) * 2017-08-01 2022-03-22 Drexel University Mxene sorbent for removal of small molecules from dialysate
CN112316157A (zh) * 2020-11-12 2021-02-05 苏州北科纳米科技有限公司 一种抗氧化MXenes材料的制备方法及应用
CN115531411B (zh) * 2022-09-19 2023-09-01 中南大学湘雅医院 一种具备ct成像和治疗双重作用的药物及其制备方法和应用
WO2024101159A1 (ja) * 2022-11-08 2024-05-16 株式会社村田製作所 医薬組成物、吸着方法、治療方法および予防方法

Similar Documents

Publication Publication Date Title
CA2455559A1 (en) Methods to mobilize progenitor/stem cells
CN1202865C (zh) 增效组合物
JP2021074025A5 (https=)
CN1140272C (zh) 抗肿瘤剂
CA2433368A1 (en) Adsorbent for oral administration
CA2277365A1 (en) Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
JP2025157552A5 (https=)
JP2013501718A5 (https=)
JP2023058678A5 (https=)
JP2005538935A5 (https=)
JP2022000060A5 (https=)
JP2002543144A5 (https=)
JP2006502117A5 (https=)
WO2004043392B1 (en) Mucin synthesis inhibitors
CN1054509C (zh) 淋巴激活素和双链rna的增效作用
JPWO2023204278A5 (https=)
JPWO2023204279A5 (https=)
US3826823A (en) Stabilized prostaglandin preparations
WO1999018993A1 (en) Ameliorant for hepatitis c remedial effect and application thereof
JP2002542256A5 (https=)
JP2688057B2 (ja) 抗腺がん剤
CN114469992A (zh) 钼基多金属氧酸盐簇在治疗炎性疾病中的应用
Zamkoff et al. A phase I trial of recombinant human macrophage colony-stimulating factor by rapid intravenous infusion in patients with refractory malignancy
JPWO2024101159A5 (https=)
JP2004506605A5 (https=)